For most of the past two decades, the standard enterprise data warehouse was treated as an engineering achievement. A single, centralized platform that ingested data from every corner of an organization, standardized it, and made it available for reporting seemed, on paper, like exactly what large regulated companies needed. In practice, it became one of the most significant technical liabilities pharmaceutical and financial services organizations carry today.
Sujit Murumkar has spent his career inside these organizations, watching the gap between what centralized systems promised and what they could actually deliver widen with each passing year. His response has been to develop and implement a fundamentally different approach, one that organizes enterprise data around business domains rather than central infrastructure, and embeds governance directly into data products rather than layering it on top of them afterward.
Why the Monolith Fails at Scale
The architecture of a traditional data warehouse assumes that a centralized team can anticipate every analytical need an organization will have and build a system capable of serving all of them from a single compute environment. That assumption held reasonably well when data volumes were predictable and analytical demands were limited to periodic batch reporting. Neither condition exists in modern pharmaceutical or financial services organizations.
IBM research on monolithic data architecture challenges documents how centralized systems force all data ingestion, transformation, and analytical queries through shared compute resources, creating bottlenecks when batch processing collides with real time analysis. Even minor changes to transformation logic require coordinated updates across ingestion pipelines, schema definitions, and reporting layers, turning what should be routine maintenance into enterprise-wide change management exercises.
The governance implications are equally serious. When all data logic lives in one system, isolating sensitive domains becomes structurally difficult. Teams responsible for clinical data, commercial data, and financial data all share the same infrastructure, the same access models, and the same update cycles. In regulated industries where GDPR, CCPA, and FDA data integrity requirements impose distinct obligations on different data types, this conflation creates compliance exposure that grows more serious as regulatory scrutiny increases.
"You cannot build a compliant, high-performance system by adding rules on top of architecture that was never designed to enforce them," Murumkar says. "Governance has to be structural. It has to be part of how the data product is built, not a policy document that lives next to it."
Data Products as the Unit of Architecture
Murumkar developed what he describes as a modular commercial data product framework, an architecture that organizes enterprise data into domain specific products rather than feeding everything into a central warehouse. Each product corresponds to a specific business domain such as customer master data, clinical trial analytics, field force performance, or market access intelligence and packages curated datasets, data quality rules, lineage metadata, and access controls together as a single deployable unit.
This approach draws on principles of data mesh architecture, which research on regulated industry implementations shows can significantly reduce governance bottlenecks by allowing domain teams to manage compliance requirements independently rather than routing every decision through a central authority. In pharmaceutical environments with dozens of markets, multiple regulatory frameworks, and highly varied analytical needs across commercial, medical, and patient services functions, this distributed model enables the kind of flexibility that centralized systems structurally cannot.
The results across Murumkar's implementations have been measurable. Data quality accuracy improved by over 40 percent through AI-driven quality checks embedded directly into data pipelines. Reporting lead times dropped by 60 percent across sales, marketing, and market access functions. Critically, the cloud native data product architecture blueprints for Data Mesh in Regulated industries, he has architected & delivered have moved beyond internal solutions to become reference models adopted across multiple top-20 pharmaceutical companies, a marker of genuine industry influence that extends well beyond any single organization.
"The measure of a good architecture is not whether it works for one team at one point in time," Murumkar explains. "It is whether other organizations look at what you built and decide it is the right model for them. When that happens, you have moved from building a solution to setting a standard."
Reusability as an Engineering Discipline
One of the most consequential aspects of Murumkar's approach is his development of reusable feature stores for machine learning deployment. In traditional pharmaceutical data environments, each new predictive model requires data science teams to rebuild the same foundational features from scratch. Customer engagement scores, physician prescribing patterns, market access indicators, and patient adherence risk signals get re-engineered for every new use case, creating redundant work and inconsistent outputs across analytical teams.
His AI-enabled insights orchestration model addresses this by creating shared feature stores that multiple teams and multiple models can draw from. When the engineering work of preparing, validating, and governing a data feature is done once and made available through a managed interface, model deployment timelines shrink dramatically. Across his implementations, this reduced the time required to deploy new machine learning models by up to 60 percent while ensuring that models trained on the same underlying features produced consistent outputs.
The approach also has significant compliance benefits in regulated environments. When feature definitions are centrally governed and consistently applied, audit trails become cleaner, model validation becomes more straightforward, and regulatory submissions that depend on analytical outputs rest on a more defensible technical foundation.
Murumkar's current work involves evolving these feature stores into Agentic AI Frameworks, Where autonomous agents navigate the data mesh to self-correct quality issues and orchestrate insights without human intervention—a shift represents the next frontier of pharmaceutical intelligence.
Migration Without Disruption
Transitioning from a legacy monolithic warehouse to a modular architecture is not a technical exercise that happens in a controlled environment. It happens while the organization continues to run, executives still need their dashboards, regulatory submissions still have deadlines, and commercial teams still need daily reporting. Murumkar led several such migrations at large-scale pharmaceutical organizations, including a migration to a distributed data lake environment using Spark, Scala, and Hive that required preserving global data harmonization while rebuilding the underlying architecture entirely.
His approach to these transitions involves establishing shared technical standards before decentralizing execution. Domain teams gain autonomy over storage formats, processing frameworks, and refresh schedules, but all products conform to common conventions for metadata, data quality metrics, and interface contracts. This structure allows different business functions to move at different speeds without creating the fragmentation that critics of decentralized architectures legitimately warn against.
"The risk with modular systems is not the architecture itself," Murumkar says. "The risk is decentralizing ownership without standardizing the contracts between systems. Get the standards right first and then give teams the autonomy to build within them. That combination is what makes the whole system trustworthy."
For pharmaceutical and financial services organizations still operating on infrastructure built for a previous era of computing, the modular data product model represents both a technical path forward and a governance upgrade. The question is not whether centralized warehouses will eventually be replaced. It is whether organizations build the successor architecture deliberately, with the standards and ownership models that make it reliable at enterprise scale, or whether they replace one set of technical debt with another.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
